Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Accumulated Expenses (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Accumulated Expenses for 7 consecutive years, with $16.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 23.15% year-over-year to $16.0 million, compared with a TTM value of $16.0 million through Dec 2025, down 23.15%, and an annual FY2025 reading of $16.0 million, down 23.15% over the prior year.
  • Accumulated Expenses was $16.0 million for Q4 2025 at Keros Therapeutics, up from $15.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $22.2 million in Q3 2024 and bottomed at $5.5 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $12.6 million, with a median of $12.5 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses skyrocketed 87.71% in 2021, then crashed 31.55% in 2025.
  • Year by year, Accumulated Expenses stood at $7.3 million in 2021, then soared by 73.77% to $12.8 million in 2022, then surged by 40.5% to $17.9 million in 2023, then rose by 16.48% to $20.9 million in 2024, then decreased by 23.15% to $16.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for KROS at $16.0 million in Q4 2025, $15.2 million in Q3 2025, and $20.0 million in Q2 2025.